The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

<div>Overall survival outcomes: (a) whole-study population and (b) per pretreatment SIRI groups (blue line: SIRI &lt; 1.9 and green line: SIRI ≥  1.9).</div>

Journal of Oncology

fig2

Figure 2

Figure 2: The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy 

Figure 2 | The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy 